Vetr Top Raters Upgrade Vital Therapies To 5-Star Stock

Loading...
Loading...
Shares of
Vital Therapies IncVTL
, a a biotherapeutic company that focuses on treatment for all forms of acute liver failure, have lost more than 60 percent over the past year, likely prompting Vetr top raters to take advantage of the recent weakness. Vetr top raters
upgraded Vital Therapies' stock rating to a 5-star out of 5 rating. In fact, shares of Vital Therapies have risen to $7.82 since the prior rating of 3.5-stars was issued just 3 days ago. Related link: Here's how crowdsourced ratings can beat the market. Despite a 5-star out of 5-star rating, Vital Therapies isn't a popular name as less than 2 percent of Vetr users are holding Vital Therapies' stock in their watch-lists. Meanwhile, 62 percent of the crowd's ratings are bullish and the crowd sourced price target of $9.28 implies an upside just shy of 20 percent.
Posted In: Analyst ColorCrowdsourcingAnalyst RatingsGeneralAcute Liver FailureBiotherapeutic StocksVetrVetr CrowdVetr Top Raters
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...